DUX4-Induced Constitutive DNA Damage and Oxidative Stress Contribute to Aberrant Differentiation of Myoblasts from FSHD Patients

Total Page:16

File Type:pdf, Size:1020Kb

DUX4-Induced Constitutive DNA Damage and Oxidative Stress Contribute to Aberrant Differentiation of Myoblasts from FSHD Patients Free Radical Biology and Medicine 99 (2016) 244–258 Contents lists available at ScienceDirect Free Radical Biology and Medicine journal homepage: www.elsevier.com/locate/freeradbiomed Original article DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients Petr Dmitriev a,b,1, Yara Bou Saada a,1, Carla Dib a, Eugénie Ansseau d, Ana Barat a, Aline Hamade e, Philippe Dessen c, Thomas Robert c, Vladimir Lazar c, Ruy A.N. Louzada g, Corinne Dupuy g, Vlada Zakharova f, Gilles Carnac b, Marc Lipinski a, Yegor S. Vassetzky a,f,n a UMR 8126, Univ. Paris-Sud, CNRS, Institut de Cancérologie Gustave-Roussy, F-94805 Villejuif, France b PhyMedExp, University of Montpellier, INSERM U1046, CNRS UMR 9214, F-34295 Montpellier cedex 5, France c Functional Genomics Unit, Institut de Cancérologie Gustave-Roussy, F-94805 Villejuif, France d Laboratory of Molecular Biology, University of Mons, 20 place du Parc, B700 Mons, Belgium e ER030-EDST, Department of Life and Earth Sciences, Faculty of Sciences II, Lebanese University, Lebanon f Lomonosov Moscow State University, Faculty of Bioengineering and Bioinformatics, 119991 Moscow, Russia g UMR 8200, Univ., Paris-Sud, CNRS, Institut de Cancérologie Gustave-Roussy, F-94805 Villejuif, France article info abstract Article history: Facioscapulohumeral dystrophy (FSHD) is one of the three most common muscular dystrophies in the Received 31 March 2016 Western world, however, its etiology remains only partially understood. Here, we provide evidence of Received in revised form constitutive DNA damage in in vitro cultured myoblasts isolated from FSHD patients and demonstrate 4 August 2016 oxidative DNA damage implication in the differentiation of these cells into phenotypically-aberrant Accepted 8 August 2016 myotubes. Double homeobox 4 (DUX4), the major actor in FSHD pathology induced DNA damage ac- Available online 9 August 2016 cumulation when overexpressed in normal human myoblasts, and RNAi-mediated DUX4 inhibition re- Keywords: duced the level of DNA damage in FSHD myoblasts. Addition of tempol, a powerful antioxidant, to the Facioscapulohumeral dystrophy culture medium of proliferating DUX4-transfected myoblasts and FSHD myoblasts reduced the level of DNA damage DNA damage, suggesting that DNA alterations are mainly due to oxidative stress. Antioxidant treatment DUX4 during the myogenic differentiation of FSHD myoblasts significantly reduced morphological defects in Oxidative stress Antioxidants myotube formation. We propose that the induction of DNA damage is a novel function of the DUX4 protein affecting myogenic differentiation of FSHD myoblasts. & 2016 Elsevier B.V. All rights reserved. 1. Introduction and a coding region for the DUX4 gene. Several studies have documented a higher level of expression of DUX4 as well as several Facioscapulohumeral dystrophy (FSHD) is an autosomal domi- proximally located genes in FSHD cells and tissues (reviewed in nant disease manifesting mainly as wasting of specific groups of [2,3]). Transcriptomic and proteomic studies have revealed an facial and limb muscles. The prevalence of FSHD is estimated to be abnormal expression of a number of mRNA, microRNAs and pro- as high as 8 in 100,000 suggesting that it might be the most teins in in vitro cultured myoblasts isolated from FSHD patients as common muscular dystrophy in the Western world [1]. FSHD has compared to healthy controls [4–18]. been genetically linked to a shortened macrosatellite repeat array In vitro cultured FSHD myoblasts which suffer from a defect in D4Z4, specific polymorphisms and sequence variants on the long the myogenic differentiation program [5], demonstrate a low fu- arm of chromosome 4 (region 4q35) which together are thought to sion index and morphological abnormalities when differentiated create a context permissive for aberrant gene expression (re- into myotubes [18,19] and are sensitive to oxidative stress [19,20]. viewed in [2,3]). In agreement with these observations, it was demonstrated that Every D4Z4 repeat on chromosome 4q35 contains a promoter the expression of oxidative stress-related genes was altered in FSHD cells [7,8,11,12,20,21] and tissues [9,22] suggesting that FSHD cells might be subjected to an endogenous oxidative stress. n Corresponding author at: UMR 8200, Univ., Paris-Sud, CNRS, Institut de Can- Increasing evidence indicates that oxidative stress can reduce cérologie Gustave-Roussy, F-94805 Villejuif, France. fi E-mail address: [email protected] (Y.S. Vassetzky). the differentiation ef ciency of human myoblasts; persistent re- 1 These authors contributed equally to this work. active oxygen species (ROS) act as signaling molecules in several http://dx.doi.org/10.1016/j.freeradbiomed.2016.08.007 0891-5849/& 2016 Elsevier B.V. All rights reserved. P. Dmitriev et al. / Free Radical Biology and Medicine 99 (2016) 244–258 245 physiological processes in human skeletal muscle cells, they are and DNA in the cell. DNA damage and genetic instability are notably known to affect their morphology and function (for review known to be involved in the etiology of many human diseases see [23,24]); both increased mitochondrial production of ROS and including cancer, neurodegenerative disorders, and aging (for re- NF-kB signaling linked to increased production of ROS can lead to view see [28,29]) and were also described in Duchenne (DMD) and muscle atrophy [25,26]. Limb-girdle Muscular (LGMD) dystrophies, but not in FSHD [30] Several previous observations suggest that increased DUX4 (for review see [31]). expression might provoke oxidative stress. DUX4, when over- Here we describe a novel phenotypic feature of in vitro cultured expressed in mouse immortalized myoblasts C2C12 or human FSHD myoblasts: a high level of DNA damage lesions, increased rhabdomyosarcoma cell line RD, altered the expression of genes production of ROS and upregulation of many genes related to DNA controlling redox balance and genes involved in the Nrf2-medi- damage repair. Furthermore, we demonstrated for the first time ated oxidative stress response pathway [21,27]. Furthermore, in- that DUX4 overexpression in human immortalized myoblasts re- ducible DUX4 overexpression in C2C12 cells rendered them more sults in a higher level of ROS in these cells. We also demonstrated sensitive to paraquat, a pro-oxidant compound [27]. However, the increased production of ROS in cells overexpressing DUX4 has that DNA damage and increased production of ROS were closely never been demonstrated directly. implicated in FSHD pathophysiology and that treatment of FSHD Oxidative stress is known to induce toxic effects through pro- myoblasts with an antioxidant during myogenic differentiation duction of peroxides and free radicals that damage proteins, lipids, significantly improved the phenotype of resulting FSHD myotubes. Fig. 1. Supervised clustering of gene expression profiles of in vitro cultured primary myoblasts (A) isolated from five healthy individuals (Norm-2,3,4,6) and six FSHD patients (FSHD-A,B,C,D,E,F) and myotubes derived from these myoblasts (B). 246 P. Dmitriev et al. / Free Radical Biology and Medicine 99 (2016) 244–258 2. Results category, Cell motility and migration, while no significant functional category could be attributed to the genes downregulated in FSHD 2.1. Transcriptome profiling of FSHD myoblasts myotubes (Table 3 and Supplementary Table S5). Several transcriptome analyses of FSHD muscles have been 2.2. DNA damage in FSHD myoblasts carried out so far, but many of these studies were done either on biopsies or on non-purified myoblasts containing contaminating In order to substantiate the transcriptomic data, we tested the fibroblasts and adipocytes [7,10,12]. To gain insight into mechan- phosphorylation of histone H2A variant H2AX at Ser-139 (γH2AX), isms of FSHD, we have analyzed transcriptional profiles in purified a marker for DNA damage that correlated with the presence of þ CD56 myoblasts and myotubes derived from either normal DNA double-stranded breaks (DSB). Using immunoblotting we subjects or FSHD patients as described elsewhere [19]. Agilent found that the overall level of γH2AX in the protein extracts of Human Genome 8 Â 44K microarrays were used to identify dif- FSHD myoblasts was significantly higher as compared to normal ferentially expressed genes as described in Materials and Methods. myoblasts (Fig. 2A and B). Immunofluorescent microscopy re- Microarray analysis of FSHD myoblasts revealed 312 up- and 88 vealed a higher percentage of nuclei with γH2AX foci in FSHD downregulated protein-coding genes (Fig. 1A), while only 71 and myoblasts than in normal cells (Fig. 2C and D). The observation 38 protein-coding genes were respectively up- and downregulated that a large number of DNA Damage Response (DDR)-related genes in FSHD myotubes (Fig. 1B) as compared to myoblasts and myo- were upregulated in FSHD myoblasts and were accompanied by a tubes isolated from healthy subjects (Table 1, Supplementary significantly higher level of γH2AX foci as well as a higher level of Tables S1, S3–6). the overall γH2AX prompted us to test the integrity of DNA in The functional annotation of 312 genes upregulated in FSHD these cells. We quantified the number of apurinic/apyrimidinic myoblasts resulted in 8 superclusters, each integrating several si- (AP)-sites using ELISA. Single-stranded breaks (SSB) and DSB milar Gene Ontology (GO) functional categories (Supplementary breaks were quantified using single-cell gel electrophoresis (comet Table S2); the three
Recommended publications
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • A Genome-Wide Association Study
    Identification of genetic variants associated with Huntington’s disease progression: a genome-wide association study Davina J Hensman Moss* 1, MBBS, Antonio F. Pardiñas* 2, PhD, Prof Douglas Langbehn 3, PhD, Kitty Lo 4, PhD, Prof Blair R. Leavitt 5, MD,CM, Prof Raymund Roos 6, MD, Prof Alexandra Durr 7, MD, Prof Simon Mead 8, PhD, the REGISTRY investigators and the TRACK-HD investigators, Prof Peter Holmans 2, PhD, Prof Lesley Jones §2 , PhD, Prof Sarah J Tabrizi §1 , PhD. * These authors contributed equally to this work § These authors contributed equally to this work 1) UCL Huntington’s Disease Centre, UCL Institute of Neurology, Dept. of Neurodegenerative Disease, London, UK 2) MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK 3) University of Iowa Carver College of Medicine, Dept. of Psychiatry and Biostatistics, Iowa, USA 4) UCL Genetics Institute, Div. of Biosciences, London, UK 5) Centre for Molecular Medicine and Therapeutics, Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia, Canada 6) Department of Neurology, Leiden University Medical Centre, Leiden, Netherlands 7) ICM and APHP Department of Genetics, Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Pitié- Salpêtrière University Hospital, Paris, France 8) MRC Prion Unit, UCL Institute of Neurology, London, UK Corresponding authors: Sarah J Tabrizi at [email protected] Lesley Jones at [email protected] 1 ABSTRACT Background Huntington’s disease (HD) is a fatal inherited neurodegenerative disease, caused by a CAG repeat expansion in HTT . Age at onset (AAO) has been used as a quantitative phenotype in genetic analysis looking for HD modifiers, but is hard to define and not always available.
    [Show full text]
  • Us 2018 / 0305689 A1
    US 20180305689A1 ( 19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 /0305689 A1 Sætrom et al. ( 43 ) Pub . Date: Oct. 25 , 2018 ( 54 ) SARNA COMPOSITIONS AND METHODS OF plication No . 62 /150 , 895 , filed on Apr. 22 , 2015 , USE provisional application No . 62/ 150 ,904 , filed on Apr. 22 , 2015 , provisional application No. 62 / 150 , 908 , (71 ) Applicant: MINA THERAPEUTICS LIMITED , filed on Apr. 22 , 2015 , provisional application No. LONDON (GB ) 62 / 150 , 900 , filed on Apr. 22 , 2015 . (72 ) Inventors : Pål Sætrom , Trondheim (NO ) ; Endre Publication Classification Bakken Stovner , Trondheim (NO ) (51 ) Int . CI. C12N 15 / 113 (2006 .01 ) (21 ) Appl. No. : 15 /568 , 046 (52 ) U . S . CI. (22 ) PCT Filed : Apr. 21 , 2016 CPC .. .. .. C12N 15 / 113 ( 2013 .01 ) ; C12N 2310 / 34 ( 2013. 01 ) ; C12N 2310 /14 (2013 . 01 ) ; C12N ( 86 ) PCT No .: PCT/ GB2016 /051116 2310 / 11 (2013 .01 ) $ 371 ( c ) ( 1 ) , ( 2 ) Date : Oct . 20 , 2017 (57 ) ABSTRACT The invention relates to oligonucleotides , e . g . , saRNAS Related U . S . Application Data useful in upregulating the expression of a target gene and (60 ) Provisional application No . 62 / 150 ,892 , filed on Apr. therapeutic compositions comprising such oligonucleotides . 22 , 2015 , provisional application No . 62 / 150 ,893 , Methods of using the oligonucleotides and the therapeutic filed on Apr. 22 , 2015 , provisional application No . compositions are also provided . 62 / 150 ,897 , filed on Apr. 22 , 2015 , provisional ap Specification includes a Sequence Listing . SARNA sense strand (Fessenger 3 ' SARNA antisense strand (Guide ) Mathew, Si Target antisense RNA transcript, e . g . NAT Target Coding strand Gene Transcription start site ( T55 ) TY{ { ? ? Targeted Target transcript , e .
    [Show full text]
  • Table S2 A375P Vs SK-MEL-2
    Supplemental Data: Table S2 tracking_id A375P SK-MEL2 Fold change des ZEB2-AS1 1.35E-286 0.315166 2.3284E+285 ZEB2 antisense RNA 1 PCDHGC5 5.45E-242 0.284138 5.2132E+240 protocadherin gamma subfamily C, 5 APOBEC3B-AS1 3.98E-240 0.130813 3.2873E+238 APOBEC3B antisense RNA 1 C6orf201 1.14E-227 0.15186 1.3345E+226 chromosome 6 open reading frame 201 LRRC24 1.93E-168 0.459062 2.3783E+167 leucine rich repeat containing 24 ZACN 3.22E-158 0.0670639 2.0857E+156 zinc activated ligand-gated ion channel LOC100506071 1.62E-144 3.33E-38 2.0564E+106 uncharacterized LOC100506071 EGFR-AS1 4.29E-101 0.0771076 1.7966E+99 EGFR antisense RNA 1 PRR5-ARHGAP8 3.44E-103 3.89E-10 1.13143E+93 PRR5-ARHGAP8 readthrough LOC100129148 8.77E-284 2.60E-214 2.96023E+69 uncharacterized LOC100129148 VLDLR-AS1 3.00E-65 0.0959249 3.20259E+63 VLDLR antisense RNA 1 ZASP 4.04E-72 4.00E-16 9.91857E+55 ZO-2 associated speckle protein SYNE1-AS1 7.86E-57 0.166307 2.11625E+55 SYNE1 antisense RNA 1 MED4-AS1 8.51E-47 0.193771 2.27656E+45 MED4 antisense RNA 1 MSTO2P 2.80E-42 0.111398 3.97942E+40 misato family member 2, pseudogene CABP7 2.99E-36 0.0263724 8.82596E+33 calcium binding protein 7 KCTD14 1.36E-151 3.05E-121 2.23303E+30 potassium channel tetramerization domain containing 14 RAET1E-AS1 1.26E-31 0.215175 1.71406E+30 RAET1E antisense RNA 1 ST7-OT3 2.06E-30 0.0817968 3.98019E+28 ST7 overlapping transcript 3 PKLR 3.86E-28 0.0268357 6.9509E+25 pyruvate kinase, liver and RBC LY75-CD302 2.64E-26 0.184984 7.01824E+24 LY75-CD302 readthrough TMEM189-UBE2V1 7.87E-23 0.322541 4.09933E+21
    [Show full text]
  • Supplementary Table 1. Copy Number Variations (CNV) Detected by XHMM (Table Is Sorted by Chromosome Intervals)
    Supplementary Table 1.
    [Show full text]
  • Impact of Non-Thermal Plasma on Cell Signaling in Keratinocytes
    Impact of non-thermal plasma on cell signaling in keratinocytes Inauguraldissertation zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) der Mathematisch-Naturwissenschaftlichen Fakultät der Ernst-Moritz-Arndt-Universität Greifswald vorgelegt von Annemarie Barton geboren am 12.04.1986 in Bielefeld Greifswald, Dezember 2013 Dekan: Prof. Dr. Klaus Fesser 1. Gutachter: Prof. Dr. Ulrike Lindequist 2. Gutachter: Prof. Dr. David Graves Datum der Verteidigung: 24.04.2014 Contents 1 Introduction 5 1.1 Plasma . .5 1.2 Human Skin . .7 1.3 Wound Healing . .8 1.3.1 Acute wound . .8 1.3.2 Chronic wound . 11 1.4 Plasma medicine . 13 1.5 Aim of the work . 14 2 Materials and Methods 15 2.1 Materials . 15 2.1.1 Chemicals and solutions . 15 2.1.2 General laboratory equipment . 16 2.1.3 Kits . 16 2.1.4 Instruments . 17 2.1.5 Software . 18 2.1.6 Buffers and solutions . 19 2.2 Methods . 19 2.2.1 Cell culture . 19 2.2.2 Plasma source . 20 2.2.3 Plasma treatment . 22 2.2.4 Preparation of conditioned medium . 23 2.2.5 Co-culture with keratinocytes and monocytes . 24 2.2.6 Cell survival . 25 2.2.7 Gene expression analysis . 26 2.2.8 Protein expression analysis . 32 3 Results 34 3.1 Impact of plasma on HaCaT cells . 34 3.1.1 Cell survival . 34 3.1.2 Transcription profile . 36 3.1.3 Secretion profile . 44 3.2 Impact of the shielding gas . 48 3.2.1 Cell survival .
    [Show full text]
  • A Genome-Wide Association Study the Lance
    Hensman Moss et al 2017 Identification of genetic variants associated with Huntington’s disease progression: a genome-wide association study Davina J Hensman Moss* , Antonio F. Pardiñas*, Douglas Langbehn, Kitty Lo, Blair R. Leavitt, Raymund Roos, Alexandra Durr, Simon Mead, Peter Holmans, Lesley Jones§, Sarah J Tabrizi§ and the REGISTRY and the TRACK-HD investigators. *Contributed equally; §Contributed equally. The Lancet Neurology 2017 Supplementary Material: Table of Contents Section Subsection Pages Supplementary 3 – 11 text Supplementary Methods 3 – 8 Supplementary Results 8 – 9 References for supplementary material 9 – 11 Investigator lists 11 – 17 TRACK-HD Investigator list 11 EHDN REGISTRY Investigator list 11 – 16 Supplementary Brief titles given below, please refer to figure for full title. Figures are listed in 17 – 30 figures the order in which they are referred to in the main then supplementary text. 1: Observed vs expected onset 17 2: Registry progression vs onset 18 3: Region plot of TRACK-HD GWAS signal in MSH3-DHFR region 19 4: Regional plot of TRACK-HD and REGISTRY meta-analysis GWAS signal in the 20 MSH3-DHFR region: conditioning on rs1232027 5: Regional plot of TRACK-HD and REGISTRY meta-analysis GWAS signal in the 21 MSH3-DHFR: conditioning on rs557874766 6: Regional plot of REGISTRY GWAS signal in the MSH3-DHFR region: 22 conditioning on rs557874766 7: Regional plot of TRACK-HD GWAS signal in MSH3-DHFR region, along with 23 GTeX eQTL associations with DHFR expression 8: Regional plot of REGISTRY GWAS signal in the
    [Show full text]
  • Probe List HTG Transcriptome Panel
    Probe List HTG Transcriptome Panel For Research Use Only. Not for use in diagnostic procedures. A1BG ABCC9 ACAD11 ACRV1 ADA ADCY1 ADM2 AGL A1CF ABCD1 ACAD8 ACSBG1 ADA2 ADCY10 ADM5 AGMAT A2M ABCD2 ACAD9 ACSBG2 ADAD1 ADCY2 ADNP AGMO A2ML1 ABCD3 ACADL ACSF2 ADAD2 ADCY3 ADNP2 AGO1 A3GALT2 ABCD4 ACADM ACSF3 ADAL ADCY4 ADO AGO2 A4GALT ABCE1 ACADS ACSL1 ADAM10 ADCY5 ADORA1 AGO3 A4GNT ABCF1 ACADSB ACSL3 ADAM11 ADCY6 ADORA2A AGO4 AAAS ABCF2 ACADVL ACSL4 ADAM12 ADCY7 ADORA2B AGPAT1 AACS ABCF2_ABCF2-H2BE1 ACAN ACSL5 ADAM15 ADCY8 ADORA3 AGPAT2 AADAC ABCF3 ACAP1 ACSL6 ADAM17 ADCY9 ADPGK AGPAT3 AADACL2 ABCG1 ACAP2 ACSM1 ADAM18 ADCYAP1 ADPRH AGPAT4 AADACL3 ABCG2 ACAP3 ACSM2A ADAM19 ADCYAP1R1 ADPRHL1 AGPAT5 AADACL4 ABCG4 ACAT1 ACSM2B ADAM2 ADD1 ADPRM AGPS AADAT ABCG5 ACAT2 ACSM3 ADAM20 ADD2 ADPRS AGR2 AAGAB ABCG8 ACBD3 ACSM4 ADAM21 ADD3 ADRA1A AGR3 AAK1 ABHD1 ACBD4 ACSM5 ADAM22 ADGB ADRA1B AGRN AAMDC ABHD10 ACBD5 ACSM6 ADAM23 ADGRA1 ADRA1D AGRP AAMP ABHD11 ACBD6 ACSS1 ADAM28 ADGRA2 ADRA2A AGT AANAT ABHD12 ACBD7 ACSS2 ADAM29 ADGRA3 ADRA2B AGTPBP1 AAR2 ABHD12B ACCS ACSS3 ADAM30 ADGRB1 ADRA2C AGTR1 AARD ABHD13 ACCSL ACTA1 ADAM32 ADGRB2 ADRB1 AGTR2 AARS1 ABHD14A ACD ACTA2 ADAM33 ADGRB3 ADRB2 AGTRAP AARS2 ABHD14A _ABHD14A-ACY1 ACE ACTB ADAM7 ADGRD1 ADRB3 AGXT AARSD1 ABHD14B ACE2 ACTBL2 ADAM8 ADGRD2 ADRM1 AGXT2 AASDH ABHD15 ACER1 ACTC1 ADAM9 ADGRE1 ADSL AHCTF1 AASDHPPT ABHD16A ACER2 ACTG1 ADAMDEC1 ADGRE2 ADSS1 AHCY AASS ABHD16B ACER3 ACTG2 ADAMTS1 ADGRE3 ADSS2 AHCYL1 AATF ABHD17A ACHE ACTL10 ADAMTS10 ADGRE5 ADTRP AHCYL2 AATK ABHD17B ACIN1 ACTL6A ADAMTS12 ADGRF1
    [Show full text]